Abstract：Objective: To observe the expression of anagenic lymphoma kinase (ALK), murine sarcoma viral oncogenic homology B1 (BRAF) and human epidermal growth factor receptor 2 (Her-2) in gastric cancer infected by Helicobacter pylori (Hp), and to analyze their prediction value of poor prognosis in HP-infected gastric cancer.Methods: A total of 106 patients with Hp-infected gastric cancer admitted to the the First Hospital of Nanping Affiliated to Fujian Medical University from October 2019 to November 2022 were selected to compare the differences in the positive rates of ALK, BRAF, and Her-2 expression in Hp-infected gastric cancer tissues and paracancerous tissues, and to analyze the relationship between the expression of ALK, BRAF, and Her-2 in gastric cancer tissues and the clinical features and pathological manifestations of Hp-infected gastric cancer. After 1 year of follow-up, the patients were divided into good prognosis group (61 cases) and poor prognosis group (45 cases) according to their postoperative recurrence or death, and the ALK, BRAF, Her-2 expression of Hp-infected gastric cancer tissues with different prognosis were compared; the predictive efficacy and early warning value of ALK, BRAF, Her-2 expression of Hp-infected gastric cancer tissues on poor prognosis were analyzed.Results: The positive rates of ALK, BRAF, and Her-2 expression in Hp-infected gastric cancer tissues (17.92%, 67.92%, and 25.47%) were higher than those in adjacent tissues (2.83%, 7.55%, and 4.72%) (χ2=12.984, 82.230, and 17.814, P<0.05). Significant differences were observed in the positive rates of ALK, BRAF, and Her-2 expression in Hp-infected gastric cancer tissues across different levels of tissue differentiation, infiltration, TNM staging, and lymph node metastasis (P<0.05). Among 106 patients with Hp-infected gastric cancer who underwent follow-up, 45 were included in the poor prognosis group (32 relapsed and 13 died), and 61 were included in the good prognosis group. The positive rates of ALK, BRAF, and Her-2 expression in Hp-infected gastric cancer tissues in the poor prognosis group (35.56%, 93.33%, and 46.67%) were higher than those in the good prognosis group (4.92%, 49.18%, and 9.84%) (χ2=16.523, 23.172, and 18.504, P<0.05). The combined assessment of ALK, BRAF, and Her-2 expression in Hp-infected gastric cancer tissues showed the highest AUC for poor prognosis, reaching 0.901 (95%CI: 0.827~0.950) (P<0.05), with a sensitivity of 86.67% and a specificity of 93.44%, and the predictive efficacy was superior to that of ALK, BRAF, and Her-2 expression detection alone. The RR values for poor prognosis caused by ALK, BRAF, and Her-2 positivity in Hp-infected gastric cancer were 2.526 (1.771~3.604), 6.611 (2.205~19.821), and 2.560 (1.733~3.781), respectively (P<0.05).Conclusion: The expression of ALK, BRAF and Her-2 in HP-infected gastric cancer is closely related to the degree of tissue differentiation, invasion, TNM staging, and lymph node metastasis, which has high predictive and early warning value for the adverse prognosis of HP-infected gastric cancer.
吴敏敏, 陈明光, 刘继英. Hp感染胃癌组织ALK BRAF Her-2表达及预测不良预后价值[J]. 河北医学, 2024, 30(12): 2073-2078.
WU Minmin, CHEN Mingguang, LIU Jiying. Expression of ALK BRAF and Her-2 in Hp-Infected Gastric Cancer Tissues and Their Predictive Value for Poor Prognosis. HeBei Med, 2024, 30(12): 2073-2078.
[1] Guan WL,He Y,Xu RH.Gastric cancer treatment:recent progress and future perspectives[J].Hematol Oncol,2023,16(1):57. [2] Kim J,Wang TC.Helicobacter pylori and gastric cancer[J].Gastrointest Endosc Clin N Am,2021,31(3):451-465. [3] 李泉星,莫旭芝,董艳霞,等.肺腺癌间变性淋巴瘤激酶突变与临床病理及CT特征的相关性研究[J].中国临床医生杂志,2022,50(1):76-80. [4] 谈啸,柏根基.细针穿刺细胞学联合BRAF基因检测对桥本甲状腺炎合并甲状腺结节良恶性的诊断价值[J].海军医学杂志,2023,44(9):925-929. [5] Burstein HJ,DeMichele A,Somerfield MR,et al.Testing for ESR1 mutations to guide therapy for hormone receptor-positive,human epidermal growth factor receptor 2-negative metastatic breast cancer:ASCO guideline rapid recommendation update[J].Clin Oncol,2023,41(18):3423-3425. [6] Horisawa N,Adachi Y,Takatsuka D,et al.The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status[J].Breast Cancer,2022,29(2):234-241. [7] Grothey A,Fakih M,Tabernero J.Management of BRAF-mutant metastatic colorectal cancer:a review of treatment options and evidence-based guidelines[J].Ann Oncol,2021,32(8):959-967. [8] 宋创业,孟艳林,刘冰,等.BRAFV600E突变蛋白及β-catenin、cyclin D1在cNO期甲状腺微小乳头状癌中的表达及意义[J].中国普通外科杂志,2022,31(11):1462-1470. [9] 郭晓鹏,王裕,马文斌.应用BRAF-MEK-MAPK信号通路抑制剂治疗BRAF V600E突变脑胶质瘤2例[J].中华神经外科杂志,2024,40(1):90-92. [10] 朱麒,肖瑶,金丽艳,等.曲妥珠单抗联合化疗对HER-2阳性胃癌患者T淋巴细胞亚群及肿瘤标志物的影响[J].临床肿瘤学杂志,2023,28(2):159-163.
2024, Vol. 30 
冀公网安备13080202000677号